Genome network medicine: Innovation to overcome huge challenges in cancer therapy

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 6, Issue 2, 2014, Pages 201-208

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC HETEROGENEITY; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84894089673     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.1254     Document Type: Article

References (61)

1. Roukos DH. Genome network medicine: new diagnostics and predictive tools. Expert Rev Mol Diagn 2013, 13:643-646.
2. Ball P. DNA: celebrate the unknowns. Nature 2013, 496:419-420.
3. Crick FH. On protein synthesis. Symp Soc Exp Biol 1958, 12:138-163.
4. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12:56-68.
5. Rask-Andersen M, Almén MS, Schiöth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011, 10:579-590.
6. ENCODE Project Consortium, Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, Epstein CB, Frietze S, Harrow J, Kaul R, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74.
7. Stamatoyannopoulos JA. What does our genome encode? Genome Res 2012, 22:1602-1611.
8. Roukos DH, Baltogiannis GG, Katsouras CS, Bechlioulis A, Naka KK, Batsis C, Liakakos T, Michalis LK. Novel next-generation sequencing and networks-based therapeutic targets: realistic more effective drug design and discovery. Curr Pharm Des (Epub ahead of print; March 19, 2013).
9. Ku CS, Roukos DH. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices 2013, 10:1-6.
10. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, Mu XJ, Khurana E, Rozowsky J, Alexander R, et al. Architecture of the human regulatory network derived from ENCODE data. Nature 2012, 489:91-100.
11. Neph S, Stergachis AB, Reynolds A, Sandstrom R, Borenstein E, Stamatoyannopoulos JA. Circuitry and dynamics of human transcription factor regulatory networks. Cell 2012, 150:1274-1286.
12. Depry C, Mehta S, Zhang J. Multiplexed visualization of dynamic signaling networks using genetically encoded fluorescent protein-based biosensors. Pflugers Arch 2013, 465:373-381.
13. Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013, 496:461-468.
14. He Y, Fang J, Taatjes DJ, Nogales E. Structural visualization of key steps in human transcription initiation. Nature 2013, 495:481-486.
15. Chung K, Wallace J, Kim SY, Kalyanasundaram S, Andalman AS, Davidson TJ, Mirzabekov JJ, Zalocusky KA, Mattis J, Denisin AK, et al. Structural and molecular interrogation of intact biological systems. Nature 2013, 497:332-337.
16. Roukos D. Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. Pharmacogenomics J 2013, 13:205-208.
17. Pelechano V, Wei W, Steinmetz LM. Extensive transcriptional heterogeneity revealed by isoform profiling. Nature 2013, 497:127-131.
18. Pugh BF. Molecular biology: the ends justify the means. Nature 2013, 497:48-49.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
20. Cho WC, Roukos DH. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. Expert Rev Anticancer Ther 2013, 13:5-8.
21. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín ÁG, López-Bonet E, Menendez JA. Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 2013, 12:225-245.
22. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al, EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
23. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
24. Roukos DH, Ku CS. Clinical cancer genome and precision medicine. Ann Surg Oncol 2012, 19:3646-3650.
25. Roukos D, Batsis C, Baltogiannis G. Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. Expert Rev Anticancer Ther 2012, 12:1245-1248.
26. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013, 339:1546-1558.
27. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012, 337:1190-1195.
28. Roukos DH, Baltogiannis GG, Baltogiannis G. Mapping inherited and somatic variation in regulatory DNA: new roadmap for common disease clinical discoveries. Expert Rev Mol Diagn 2013, 13:519-522.
29. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res 2012, 22:1748-1759.
30. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013, 45:353-361.
31. Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet 2013, 45:345-348.
32. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, Edlund CK, Haile RW, Gallinger S, Zanke BW, et al. Meta-analysis of newgenome-wide association studiesofcolorectal cancerrisk. Hum Genet 2012, 131:217-234.
33. Parikh H, Jia J, Zhang X, Chung CC, Jacobs KB, Yeager M, Boland J, Hutchinson A, Burdett L, Hoskins J, et al. A resequence analysis of genomic loci on chromosomes 1q32.1, 5p15.33, and 13q22.1 associated with pancreatic cancer risk. Pancreas 2013, 42:209-215.
34. Zhang R, Zhao Y, Chu M, Wu C, Jin G, Dai J, Wang C, Hu L, Gou J, Qian C, et al. Pathway analysis forgenome-wide association studyoflung cancerin Han Chinese population. PLoS One 2013, 8(3):e57763.
35. Zhang JX, Zhang J, Yan W, Wang YY, Han L, Yue X, Liu N, You YP, Jiang T, Pu PY, et al. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes ofglioblastoma. Neuro Oncol 2013, 15:279-289.
36. Yang XX, Li FX, Zhou CP, Hu NY, Wu YS, Li M. Associationofgenetic polymorphismsat1q22but not 10q23 with gastric cancer in a southern Chinese population. Asian Pac J Cancer Prev 2012, 13:2519-2522.
37. Wang M, Zhang R, He J, Qiu L, Li J, Wang Y, Sun M, Yang Y, Wang J, Yang J, et al. PotentiallyfunctionalvariantsofPLCE1identifiedbyGWASscontributetogastricadenocarcinomasusceptibility in an eastern Chinese population. PLoS One 2012, 7(3):e31932.
38. Zhang H, Jin G, Li H, Ren C, Ding Y, Zhang Q, Deng B, Wang J, Hu Z, Xu Y, et al. Genetic variants at 1q22 and 10q23 reproducibly associated with gastric cancer susceptibility in a Chinese population. Carcinogenesis 2011, 32:848-852.
39. Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 2010, 42:764-767.
40. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
41. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
42. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
43. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
44. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
45. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
46. International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, et al. International network of cancer genome projects. Nature 2010, 464:993-998.
47. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
48. Fernández A, Lynch M. Non-adaptive origins of interactome complexity. Nature 2011, 474:502-505.
49. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
50. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
51. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013, 497:378-382.
52. Alberts B. Model organisms and human health. Science 2010, 330:1724.
53. Anonymous. Time for the epigenome, editorial. Nature 2010, 463:587.
54. Thurman RE, Day N, Noble WS, Stamatoyannopoulos JA. Identification of higher-order functional domains in the human ENCODE regions. Genome Res 2007, 17:917-927.
55. Vernot B, Stergachis AB, Maurano MT, Vierstra J, Neph S, Thurman RE, Stamatoyannopoulos JA, Akey JM. Personal and population genomics of human regulatory variation. Genome Res 2012, 22:1689-1697.
56. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature 2012, 489:109-113.
57. Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X, Gueroussov S, Albu M, Zheng H, Yang A, et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature 2013, 499:172-177.
58. Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, Merkurjev D, Zhang J, Ohgi K, Song X, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 2013, 498:516-520.
59. Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, Sheffield NC, Stergachis AB, Wang H, Vernot B, et al. The accessible chromatin landscape of the human genome. Nature 2012, 489:75-82.
60. de Wit E, Bouwman BA, Zhu Y, Klous P, Splinter E, Verstegen MJ, Krijger PH, Festuccia N, Nora EP, Welling M, et al. The pluripotent genome in three dimensions is shaped around pluripotency factors. Nature 2013, 501:227-231.
61. Powell D. Quark quartet opens fresh vista on matter. Nature 2013, 498:280-281.